Zachariah Serber - Feb 14, 2022 Form 4 Insider Report for Zymergen Inc. (ZY)

Role
Chief Science Officer, Director
Signature
/s/ Mina Kim, attorney-in-fact
Stock symbol
ZY
Transactions as of
Feb 14, 2022
Transactions value $
-$21,730
Form type
4
Date filed
2/16/2022, 04:45 PM
Previous filing
Feb 9, 2022
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZY Common Stock Sale -$21.7K -5.44K -0.23% $4.00 2.37M Feb 14, 2022 Direct F1, F2
holding ZY Common Stock 40K Feb 14, 2022 See Footnote F3
holding ZY Common Stock 40K Feb 14, 2022 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2021 that provides for the sale of up to 250,000 shares over the next ten (10) months, which started January 24, 2022.
F2 Transaction executed in multiple trades at prices ranging from $3.91 to $4.12 per share, inclusive. The price reported in column 4 above reflects the weighted average sale price per share. The Reporting Person hereby undertakes to provide the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Held by the Rorik Serber 2021 Irrevocable Trust.
F4 Held by spouse as custodian for children under the California Uniform Transfer to Minors Act.